NCT02917304

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older

A Multicenter, Open-label, Single Arm Study to Evaluate the Immunological Efficacy and Safety of GC3110A. Administered Intramuscularly in Healthy Subjects Aged 65 Years and Older

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 274 (actual)
• Sponsor: Green Cross Corporation · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate immunological efficacy and safety of GC3110A among healthy adults over 65 years of age.

Detailed description

Adults over 65 years of age will be once administered GC3110A(Quadrivalent influenza vaccine).

Conditions

• Influenza, Human

Interventions

Type	Name	Description
BIOLOGICAL	GC3110A vaccine	0.5mL, Intramuscular

Timeline

• Start date: 2016-10-10
• Primary completion: 2016-12-02
• Completion: 2017-05-08
• First posted: 2016-09-28
• Last updated: 2017-05-30

Locations

10 sites across 1 country: South Korea